Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2007; 13(44): 5845-5856
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5845
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5845
Table 1 Agents targeting EGFR pathway in GI cancers
Agents | Tumor types | Regimen | Study design | References |
Monoclonal antibodies | ||||
Cetuximab | Colorectal cancer | Irinotecan/cetuximab | Phase III | [9] |
Hepatocellular carcinoma | Cetuximab | Phase II | [27] | |
Pancreatic cancer | Gemcitabine/cetuximab | Phase II | [28] | |
Pancreatic cancer | Gemcitabine/RT/cetuximab | Phase II | [29] | |
Panitumumab | Colorectal carcinoma | Panitumumab | Phase III | [47] |
Matuzumab | Pancreatic cancer | Gemcitabine/matuzumab | PhaseI | [60] |
Colorectal cancer | Matuzumab | PhaseI | [61] | |
Tyrosine kinase inhibitors | ||||
Erlotinib | Pancreatic cancer | Gemcitabine/erlotinib | Phase III | [52] |
Colorectal cancer | CapOx/erlotinib | Phase II | [54] | |
Hepatocellular carcinoma | Erlotinib | Phase II | [56] | |
Colorectal cancer | FOLFIRI/erlotinib | PhaseI | [55] | |
Pancreatic cancer | Gemcitabine/paclitaxol/RT/erlotinib | PhaseI | [62] | |
Geftinib | Colorectal cancer | Gefitinib/fluorouracil/oxaliplatin | Phase II | [63] |
Colorectal cancer | Gefitinib/oxaliplatin | Phase II | [64] | |
Colorectal cancer | Gefitinib | Phase II | [65,66] | |
Hepatocellular carcinoma | Gefitinib | Phase II | [67] | |
Pancreatic and rectal cancer | Capecitabine/gefitinib/RT | PhaseI | [68] | |
Lapatinib | Colorectal cancer | Lapatinib | Phase II | [59] |
Table 2 Agents targeting angiogenesis in GI cancers
Agents | Tumor types | Regimen | Study Design | References |
Monoclonal antibodies | ||||
Bevacizumab | Colorectal cancer | Bevacizumab/IFL | Phase III | [10] |
Bevacizumab/FOLFOX (E3200) | Phase III | [99] | ||
Bevacizumab/FOLFIRI | Phase II | [102] | ||
Pancreatic cancer | Bevacizumab/gemcitabine | Phase II/III | [103] | |
Bevacizumab/gemcitabine/oxaliplatin | Phase II | [105] | ||
Bevacizumab/capecitabine/RT | PhaseI | [124] | ||
VEGF decoy | ||||
VEGF-Trap | Solid tumors | I-LV5FU2/ VEGF-Trap | PhaseI | [111] |
Solid tumors | FOLFOX4/ VEGF-Trap | PhaseI | [112] | |
Tyrosine kinase inhibitors | ||||
Sorafenib | Hepatocellular carcinoma | Sorafenib | Phase III | [8] |
Pancreatic cancer | Gencitabine/sorafenib | PhaseI | [116] | |
Colorectal cancer | Oxaliplatin/sorafenib | PhaseI | [115] | |
Sunitinib | Colorectal cancer | Irinotecan/cetuximab/sunitinib | PhaseI/II | [122] |
Hepatocellular carcinoma | Sunitinib | PhaseI/II | [121,123] |
- Citation: Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol 2007; 13(44): 5845-5856
- URL: https://www.wjgnet.com/1007-9327/full/v13/i44/5845.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i44.5845